Eli Lilly and Comp. (LLY) Stock Forecast for 2024–2028. Sell or Buy Prediction







Maximizing Profits: When is the Right Time to Sell Your Business?

April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?

Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
Improve Your Financial Status: A How-To Guide

April 12, 2024 Improve Your Financial Status: A How-To Guide

Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
How ZIM Integrated Container Tracking is Revolutionizing Global Trade

April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade

Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
6 Best Growth Stocks To Buy Now According to Metatrader 5

March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5

One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…

Eli Lilly and Comp. (LLY) Stock Forecast for 2024–2028. Sell or Buy?

Updated: July 17, 2024 (19:50)

Sector: Healthcare

The share price of Eli Lilly and Company (LLY) now

Latest session on the 17th of July for
Eli Lilly and Company is negative
Trading Volume: 4193505
Open: 910.01 /  High: 924.63 /  Low: 902.76
What analysts predict: $899.35
52-week High/Low: $966.1 / $443.25

50/200 Day Moving Average: $849.88 / $709.3

This figure corresponds to the Average Price over the previous 50/200 days. For Eli Lilly and Comp. stocks, the 50-day moving average is the support level today.

For Eli Lilly and Comp. stocks, the 200-day moving average is the support level today.

Are you interested in Eli Lilly and Company stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Eli Lilly and Comp. stock price in 2024, 2025, 2026, 2027, 2028. How much will one Eli Lilly and Comp. share be worth in 2024 - 2028?

When should I take profit in Eli Lilly and Comp. stock? When should I record a loss on Eli Lilly and Comp. stock? What are analysts' forecasts for Eli Lilly and Comp. stock? What is the future of Eli Lilly and Comp. stock? We forecast Eli Lilly and Comp. stock performance using neural networks based on historical data on Eli Lilly and Comp. stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.

Eli Lilly and Comp. stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2024, 2025, 2026, 2027 and 2028) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Eli Lilly and Comp. shares. This happens once a day.


Historical and forecast chart of Eli Lilly and Comp. stock

The chart below shows the historical price of Eli Lilly and Comp. stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Eli Lilly and Comp. stock price can be found in the table below.

Long-term forecasts by years.

Unveiling the Future: What's Next for Eli Lilly's LLY Stock?

Trend: Neutral
Jul 09, 2024

Investors and analysts keenly eyeing Eli Lilly's (LLY) stock can anticipate several pivotal moments capable of swaying its market value. At the forefront is the eagerly awaited Phase 2b trial results of MORF-057. These results stand as a crucial determinant of LLY stock forecast, holding the power to either catapult the company's value through demonstrated efficacy and safety or cast shadows of doubt on its potential by failing to meet expectations. The LLY stock buy or sell decision hinges significantly on this outcome, making it the apex concern for market watchers.

The Road Ahead: Strategic Insights for LLY's Stock

However, the complexities of forecasting stock movements extend beyond a single drug trial. Analysts looking to make the most accurate LLY stock price predictions must also scrutinize the competitive dynamics within the inflammatory bowel disease (IBD) market. Drugs like Takeda's Entyvio set a high benchmark, and their performance could influence investor sentiment towards LLY, potentially altering the LLY stock price target.

Moreover, the progress of Morphic's preclinical pipeline, particularly the oral candidates targeting IL23 and TL1A, adds another layer of considerations for those debating whether Eli Lilly and Comp. stock is a buy or sell. Success here could enrich LLY's long-term prospects, underscoring the importance of looking beyond immediate trial results to the broader R&D landscape when making LLY stock price predictions.

In essence, a well-rounded analysis encompassing upcoming trial results, competitive market performance, and R&D milestones stands as the best approach for those wrestling with the decision to buy or sell LLY stock. Keeping a close eye on these factors will equip analysts and investors alike to navigate the undulating prospects of Eli Lilly's future.

Review the original Analysis
About author

Eli Lilly's Soaring Stock Prospects: Tirzepatide and Beyond

Trend: Neutral
Jul 08, 2024

In an era where drug development is king, Eli Lilly (LLY) stands out with its impressive lineup of potential blockbuster drugs, ready to redefine its industry standing. The near future for LLY stocks seems particularly promising, ignited by a series of anticipated events and breakthrough developments. At the forefront is tirzepatide, Eli Lilly's crown jewel, predicted to amass over $50 billion in peak annual sales. This diabetes and obesity treatment has already fueled optimistic LLY stock forecasts, positioning Lilly as a heavyweight in both market dominance and investor confidence.

A Closer Look at Potential Market Movers

Yet, tirzepatide is only part of the equation. The success of MORF-057 in addressing inflammatory bowel disease (IBD) could further catapult LLY stocks. As analysts pore over trial results, the performance of MORF-057 will be closely watched, its success potentially reshaping LLY stock price predictions. Furthermore, the potential approval and success of Lebrikizumab and Mirikizumab, aimed at Atopic Dermatitis and Ulcerative Colitis respectively, mark another critical juncture for Eli Lilly. Their market entry could significantly impact whether LLY stock is a buy or sell.

For analysts aiming to make accurate predictions on the Eli Lilly and Comp. stock forecast, these developments offer a fertile ground for analysis. By carefully evaluating the clinical and market potential of these products, analysts can offer more precise LLY stock price targets, providing valuable insights for investors considering whether Eli Lilly and Comp. stock is a good buy. For savvy investors keeping an eye on the pharmaceutical sector, these factors could well define the trajectory of LLY's stock in the foreseeable future.

Review the original Analysis
About author

Kisunla Approval Stirs Positive Outlook for Eli Lilly's LLY Stock Forecast

Trend: Bullish
Jul 03, 2024

The recent FDA nod for Eli Lilly’s Alzheimer’s drug, Kisunla, sets the stage for a major influence on the LLY stock rates. Market analysts eyeing the Eli Lilly and Comp. name stock forecast are particularly enthusiastic about the potential competitive edge Kisunla introduces over Biogen's Leqembi. Its unique treatment regimen, promising a better amyloid plaque reduction, positions Kisunla not just as a therapy but a beacon for investor interest, potentially making LLY a good stock to buy. Analysts predict such groundbreaking approvals to boost sales, directly feeding into a positive LLY stock price prediction.

Using Key Factors to Forecast LLY Stock Changes

Analysts focusing on whether LLY stock is a buy or sell take into account several factors. First, the company's rousing Q1 revenue surge by 26% fueled by diabetes and obesity drugs, setting a favorable backdrop. The expanding Alzheimer’s market, estimated to exceed $10 billion by 2029, with Kisunla pegged as a blockbuster drug, further solidifies its stance. When forecasting, analysts juxtapose these elements with the company's valuation and peer comparison, crafting a well-rounded LLY stock price target and answering the looming question—is LLY a good stock to buy now?

By dissecting elements like Kisunla’s approval, revenue growth, market potential, and Eli Lilly’s financial health, predicting the trajectories of LLY stock rates becomes tangible. This meticulous approach allows investors to navigate their decisions, cementing Eli Lilly and Comp. stock as a notable contender in their portfolios.

Review the original Analysis
About author

Eli Lilly and Company is an American pharmaceutical company. It was founded in 1876 in Indianapolis, Indiana, where its headquarters are still located. It is known as the first company to start the industrial production of insulin (in 1923). The company operates in two areas: medicines for humans and veterinary medicines (a division of Elanco). The company’s products are sold in 120 countries.

www.lilly.com

Eli Lilly and Comp. daily forecast for a month

Date Target Pes. Opt. Vol., %
Jul 19 967.82 959.69 974.78 1.57
Jul 20 965.78 952.75 981.14 2.98
Jul 21 975.63 963.05 992.90 3.10
Jul 22 953.98 934.51 970.57 3.86
Jul 23 972.01 951.30 978.13 2.82
Jul 24 967.34 953.99 976.63 2.37
Jul 25 953.12 936.25 969.70 3.57
Jul 26 962.27 948.12 980.75 3.44
Jul 27 958.81 941.26 974.05 3.48
Jul 28 970.89 951.37 983.12 3.34
Jul 29 957.49 948.01 963.52 1.64
Jul 30 982.77 959.47 991.91 3.38
Jul 31 970.68 958.74 983.78 2.61
Aug 01 961.94 949.24 977.24 2.95
Aug 02 968.29 952.02 991.24 4.12
Aug 03 987.75 975.60 1 002.57 2.76
Aug 04 985.98 974.44 997.81 2.40
Aug 05 1 009.64 986.92 1 019.03 3.25
Aug 06 980.26 959.38 1 003.49 4.60
Aug 07 967.32 945.26 979.80 3.65
Aug 08 971.09 954.78 989.15 3.60
Aug 09 979.54 956.62 988.94 3.38
Aug 10 1 005.11 998.77 1 015.96 1.72
Aug 11 1 024.10 1 000.75 1 045.92 4.51
Aug 12 1 041.61 1 031.30 1 051.61 1.97
Aug 13 1 039.11 1 029.76 1 059.07 2.85
Aug 14 1 021.97 1 006.33 1 029.02 2.25
Aug 15 995.30 980.37 1 015.90 3.62
Aug 16 977.68 961.55 993.52 3.32
Aug 17 962.13 949.43 975.12 2.71

Eli Lilly and Comp. Daily Price Targets


Eli Lilly and Comp. Stock Forecast 07-19-2024.

Forecast target price for 07-19-2024: $967.82.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 1.549%.
Pessimistic target level: 959.69
Optimistic target level: 974.78

Eli Lilly and Comp. Stock Forecast 07-20-2024.

Forecast target price for 07-20-2024: $965.78.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.894%.
Pessimistic target level: 952.75
Optimistic target level: 981.14

Eli Lilly and Comp. Stock Forecast 07-21-2024.

Forecast target price for 07-21-2024: $975.63.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.007%.
Pessimistic target level: 963.05
Optimistic target level: 992.90

Eli Lilly and Comp. Stock Forecast 07-22-2024.

Forecast target price for 07-22-2024: $953.98.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.715%.
Pessimistic target level: 934.51
Optimistic target level: 970.57

Eli Lilly and Comp. Stock Forecast 07-23-2024.

Forecast target price for 07-23-2024: $972.01.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.743%.
Pessimistic target level: 951.30
Optimistic target level: 978.13

Eli Lilly and Comp. Stock Forecast 07-24-2024.

Forecast target price for 07-24-2024: $967.34.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.318%.
Pessimistic target level: 953.99
Optimistic target level: 976.63

LLY (LLY) Monthly Stock Prediction for 2024

Month Target Pes. Opt. Vol., %
Aug. 1 045.75 972.34 1 131.39 14.06
Sep. 1 147.71 1 067.14 1 262.59 15.48
Oct. 1 119.36 1 008.77 1 173.20 14.02
Nov. 994.21 923.13 1 067.89 13.56
Dec. 986.46 960.81 1 080.07 11.04

Eli Lilly and Comp. forecast for this year


Eli Lilly and Comp. Stock Prediction for Aug 2024

An uptrend is forecast for this month with an optimal target price of $1045.75. Pessimistic: $972.34. Optimistic: $1 131.39


Eli Lilly and Comp. Stock Prediction for Sep 2024

An uptrend is forecast for this month with an optimal target price of $1147.71. Pessimistic: $1 067.14. Optimistic: $1 262.59


Eli Lilly and Comp. Stock Prediction for Oct 2024

An downtrend is forecast for this month with an optimal target price of $1119.36. Pessimistic: $1 008.77. Optimistic: $1 173.20


Eli Lilly and Comp. Stock Prediction for Nov 2024

An downtrend is forecast for this month with an optimal target price of $994.214. Pessimistic: $923.13. Optimistic: $1 067.89


Eli Lilly and Comp. Stock Prediction for Dec 2024

An downtrend is forecast for this month with an optimal target price of $986.46. Pessimistic: $960.81. Optimistic: $1 080.07



Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2025

Month Target Pes. Opt. Vol., %
Jan 1 024.93 942.32 1 104.88 14.71
Feb 1 032.93 988.61 1 125.58 12.17
Mar 979.21 890.11 1 018.68 12.62
Apr 1 004.67 955.04 1 042.55 8.39
May 1 119.61 1 055.57 1 158.91 8.92
Jun 1 058.48 948.40 1 146.54 17.28
Jul 1 121.77 1 080.94 1 216.56 11.15
Aug 1 257.40 1 152.78 1 322.78 12.85
Sep 1 355.47 1 274.42 1 470.01 13.31
Oct 1 293.80 1 174.38 1 342.58 12.53
Nov 1 280.34 1 178.81 1 316.96 10.49
Dec 1 227.08 1 123.39 1 353.10 16.98

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2026

Month Target Pes. Opt. Vol., %
Jan 1 222.30 1 130.14 1 274.73 11.34
Feb 1 331.94 1 295.57 1 444.48 10.31
Mar 1 200.34 1 159.77 1 281.48 9.50
Apr 1 169.13 1 061.22 1 228.41 13.61
May 1 245.13 1 118.87 1 335.77 16.24
Jun 1 264.55 1 230.03 1 396.06 11.89
Jul 1 211.94 1 134.74 1 267.09 10.45
Aug 1 344.29 1 288.37 1 450.89 11.20
Sep 1 325.07 1 225.16 1 437.03 14.74
Oct 1 238.94 1 122.97 1 356.51 17.22
Nov 1 277.59 1 222.78 1 375.58 11.11
Dec 1 123.13 1 023.85 1 215.11 15.74

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2027

Month Target Pes. Opt. Vol., %
Jan 1 169.85 1 061.88 1 206.35 11.98
Feb 1 058.83 985.88 1 167.58 15.56
Mar 1 144.18 1 053.44 1 199.21 12.16
Apr 1 144.18 1 057.90 1 248.30 15.25
May 1 276.56 1 236.73 1 404.34 11.94
Jun 1 218.47 1 150.36 1 305.59 11.89
Jul 1 367.37 1 230.50 1 411.81 12.84
Aug 1 458.03 1 327.24 1 543.32 14.00
Sep 1 566.07 1 415.41 1 680.08 15.75
Oct 1 696.36 1 546.41 1 786.78 13.45
Nov 1 806.63 1 661.01 1 917.01 13.35
Dec 1 630.48 1 539.34 1 797.93 14.38

Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2028

Month Target Pes. Opt. Vol., %
Jan 1 577.49 1 505.71 1 684.13 10.59
Feb 1 585.69 1 497.05 1 653.72 9.47
Mar 1 606.31 1 518.60 1 664.78 8.78
Apr 1 641.81 1 554.30 1 697.30 8.43
May 1 618.33 1 492.10 1 677.24 11.04
Jun 1 578.36 1 479.87 1 629.65 9.19
Jul 1 728.14 1 566.39 1 894.39 17.31
Aug 1 723.65 1 555.59 1 822.24 14.63
Sep 1 656.43 1 609.05 1 820.08 11.59
Oct 1 733.95 1 634.77 1 871.45 12.65
Nov 1 790.30 1 671.60 1 918.31 12.86
Dec 1 711.17 1 619.96 1 760.11 7.96

Eli Lilly and Comp. information and performance

Eli Lilly and Comp. Address

LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US

Market Capitalization: 847 821 341 000 $

Market capitalization of the Eli Lilly and Company is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of LLY shares in the company outstanding by the market price of one share.

EBITDA: 13 373 700 000 $

EBITDA of Eli Lilly and Comp. is earnings before interest, income tax and depreciation of assets.

PE Ratio: 138.88

P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit

PEG Ratio: 1.431

Price/earnings to growth

DPS: 4.69

Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.

DY: 0.0055

Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.

EPS: 6.78

EPS shows how much of the net profit is accounted for by the common share.

Quarterly Earnings Growth YOY: 0.664
Quarterly Revenue Growth YOY: 0.26
Trailing PE: 138.88

Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.

Forward PE: 60.24

Forward P/E uses projections of future earnings instead of final numbers.

EV To Revenue: 21.6

Enterprise Value (EV) /Revenue

EV To EBITDA: 86.01

The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).

Shares Outstanding: 900405000

Number of issued ordinary shares

Shares Float: N/A

Number of freely tradable shares

Shares Short Prior Month: N/A

Shares Short Prior Month - the number of shares in short positions in the last month.

Short Ratio: N/A
Percent Insiders: N/A
Percent Institutions: N/A

Eli Lilly and Comp. (LLY) stock dividend

Eli Lilly and Comp. last paid dividends on 08/15/2024. The next scheduled payment will be on 09/10/2024. The amount of dividends is $4.69 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.

Last Split Factor:

Last Split Date: 01/01/1970

Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.

For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.




Related stocks from Healthcare sector


Disclaimer:

All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.